CORRIGENDUM

to the Press Release of

2337th Council meeting

- JUSTICE, HOME AFFAIRS AND CIVIL PROTECTION -

Brussels, 15 and 16 March 2001
ITEM: MIXED COMMITTEE MEETING AT MINISTERIAL LEVEL

Page 13, first paragraph, first line and page 14, first line of third and fourth paragraphs

Replace "The Council" by "The Mixed Committee".

ITEM: GHB and Ketamine (new synthetic drugs)

Pages III and IV

The Council conclusions should read as follows:

- on GHB:

"The Council

- taking into account the conclusions in the Report from the Commission to the Council called for by the Joint Action on New Synthetic Drugs (97/396/JHA) concerning GHB, recommends active monitoring of GHB during 2001.

- invites the EMCDDA and Europol to monitor in the framework of their respective work programmes and in cooperation with the Member States, any new supplementary information in the fields of consumption, trafficking and public health related problems, and particularly to collate information on:
  - clinical effects (deaths, overdose cases, hospital admissions) associated with GHB, as well as data sources and investigation methods;
  - prevalence and patterns of non-medical use and behaviours of users;
  - seizures and any other information on the type of products in use (powder, tablets, liquid, etc.);
  - the role of organized crime in the production, diversion and trafficking of GHB;
  - the use of internet for marketing of GHB for non-medical purposes.

- invites the Member States to forward to the EMCDDA relevant legal texts and information on related control measures in order to be able to appreciate the impact of the different existing control systems as well as information on the real extent of therapeutic use of GHB.

- invites the Commission to inform the Council on the state of negotiations with the chemical industry for possible mechanisms in order to limit the diversion of GHB and its precursors and on the state of information of the pharmaceutical industry.

- encourages the Member States to share information on preventive and risk reduction measures related to non-medical use of GHB including appropriate messages targeting users of GHB.
- invites the EMCDDA and Europol to present a progress report to the Council, preferably before 31 December 2001.

- invites the Commission to take into account the outcome of the risk assessment of GHB in the evaluation of the effectiveness of the Joint Action called for in the EU Action Plan on Drugs 2000-2004, particularly in point 2.2.5.

- on **Ketamine**:

"The Council,

Taking into account the conclusions in the Report from the Commission to the Council called for by the Joint Action on New Synthetic Drugs (97/396 JHA) concerning ketamine,

- encourages EMCDDA and Europol to continue monitoring, in the framework of their respective work programmes and in cooperation with the Member States, the manufacture, trafficking, patterns of use and health consequences of ketamine, particularly the trends in recreational use;

- suggests that possible improvements in the control of diversion be discussed with the chemical and pharmaceutical industry, bearing in mind the importance of ensuring the continued availability of ketamine for medical and veterinary use;

- encourages Member States to present proposals for research on the effects of ketamine use to be considered under the Fifth Framework Program for Research and Development;

- invites the Commission to take into account the outcome of the risk assessment of ketamine in the evaluation of the effectiveness of the Joint Action called for in the EU Action Plan on Drugs 2000-2004, particularly in point 2.2.5."